

# Robert M Califf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7291347/publications.pdf>

Version: 2024-02-01

244  
papers

25,964  
citations

14614

66  
h-index

6454

157  
g-index

257  
all docs

257  
docs citations

257  
times ranked

26196  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
2	Regression modelling strategies for improved prognostic prediction. <i>Statistics in Medicine</i> , 1984, 3, 143-152.	0.8	1,486
3	Scientific Evidence Underlying the ACC/AHA Clinical Practice Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 831.	3.8	774
4	Biomarker definitions and their applications. <i>Experimental Biology and Medicine</i> , 2018, 243, 213-221.	1.1	722
5	Ethical and Scientific Implications of the Globalization of Clinical Research. <i>New England Journal of Medicine</i> , 2009, 360, 816-823.	13.9	628
6	The ClinicalTrials.gov Results Database " Update and Key Issues. <i>New England Journal of Medicine</i> , 2011, 364, 852-860.	13.9	628
7	Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 920-926.	1.6	582
8	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1999, 100, 14-20.	1.6	532
9	Launching PCORnet, a national patient-centered clinical research network. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 578-582.	2.2	491
10	Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1838.	3.8	403
11	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
12	Use of Medical Resources and Quality of Life after Acute Myocardial Infarction in Canada and the United States. <i>New England Journal of Medicine</i> , 1994, 331, 1130-1135.	13.9	322
13	Compliance with Results Reporting at ClinicalTrials.gov. <i>New England Journal of Medicine</i> , 2015, 372, 1031-1039.	13.9	319
14	Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 1999, 100, 2045-2048.	1.6	281
15	Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International) Trial. <i>Journal of the American Heart Association</i> , 2008, 156, 826-832.	1.2	280
16	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015, 36, 288-296.	1.0	266
17	Analyses of Cancer Data from Three Ezetimibe Trials. <i>New England Journal of Medicine</i> , 2008, 359, 1357-1366.	13.9	230
18	Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation. <i>Circulation</i> , 1999, 100, 2067-2073.	1.6	225

#	ARTICLE	IF	CITATIONS
19	Relationship Between Diabetes Mellitus and Long-term Survival After Coronary Bypass and Angioplasty. <i>Circulation</i> , 1997, 96, 2551-2556.	1.6	225
20	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	1.2	212
21	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet, The</i> , 2014, 383, 2008-2017.	6.3	194
22	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014, 383, 1059-1066.	6.3	186
23	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
24	Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2014, 130, 1445-1451.	1.6	181
25	Patients Who Want their Family and Physician to Make Resuscitation Decisions for Them: Observations from SUPPORT and HELP. <i>Journal of the American Geriatrics Society</i> , 2000, 48, S84-90.	1.3	179
26	Impact of an Aggressive Invasive Catheterization and Revascularization Strategy on Mortality in Patients With Cardiogenic Shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. <i>Circulation</i> , 1997, 96, 122-127.	1.6	177
27	A Multicenter, Randomized Trial of Coronary Angioplasty Versus Directional Atherectomy for Patients With Saphenous Vein Bypass Graft Lesions. <i>Circulation</i> , 1995, 91, 1966-1974.	1.6	169
28	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	1.2	168
29	Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. <i>Circulation</i> , 2020, 141, e615-e644.	1.6	168
30	Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. <i>Circulation</i> , 1998, 97, 1702-1707.	1.6	163
31	Surrogate and Physician Understanding of Patients' Preferences for Living Permanently in a Nursing Home. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 818-824.	1.3	160
32	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. <i>Circulation</i> , 1999, 99, 1951-1958.	1.6	154
33	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
34	Recent Trends in the Care of Patients With Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>Archives of Internal Medicine</i> , 2006, 166, 2027.	4.3	153
35	Sensible approaches for reducing clinical trial costs. <i>Clinical Trials</i> , 2008, 5, 75-84.	0.7	153
36	Exploring the ethical and regulatory issues in pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 436-441.	0.7	153

#	ARTICLE	IF	CITATIONS
37	Thrombolytic Therapy for Acute Myocardial Infarction. <i>Drugs</i> , 1992, 44, 293-325.	4.9	145
38	Integrating quality into the cycle of therapeutic development. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1895-1901.	1.2	145
39	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	1.0	145
40	Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1069.	3.8	144
41	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	1.0	142
42	Prediction of 1-Year Survival After Thrombolysis for Acute Myocardial Infarction in the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. <i>Circulation</i> , 2000, 101, 2231-2238.	1.6	133
43	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
44	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet</i> , The, 2015, 385, 2363-2370.	6.3	123
45	Transforming Evidence Generation to Support Health and Health Care Decisions. <i>New England Journal of Medicine</i> , 2016, 375, 2395-2400.	13.9	123
46	Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry. <i>Circulation</i> , 2000, 101, 2682-2689.	1.6	119
47	Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty. <i>Circulation</i> , 1996, 94, 629-635.	1.6	119
48	The Landscape of Clinical Trials in Nephrology: A Systematic Review of ClinicalTrials.gov. <i>American Journal of Kidney Diseases</i> , 2014, 63, 771-780.	2.1	118
49	Ethics and Regulatory Complexities for Pragmatic Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2381.	3.8	114
50	Physician Understanding Of Patient Resuscitation Preferences: Insights and Clinical Implications. <i>Journal of the American Geriatrics Society</i> , 2000, 48, S44-51.	1.3	110
51	Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2000, 101, 366-371.	1.6	106
52	Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2000, 101, 751-757.	1.6	104
53	Randomized Clinical Trials – Removing Unnecessary Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 1061-1065.	13.9	103
54	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	1.9	103

#	ARTICLE	IF	CITATIONS
55	Principles From Clinical Trials Relevant to Clinical Practice: Part I. <i>Circulation</i> , 2002, 106, 1015-1021.	1.6	98
56	A comparison of phenotype definitions for diabetes mellitus. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, e319-e326.	2.2	96
57	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1852.	3.8	94
58	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	1.9	91
59	An update on the IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. <i>American Heart Journal</i> , 2010, 159, 705-709.	1.2	82
60	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. <i>JAMA Cardiology</i> , 2019, 4, 846.	3.0	81
61	Clinical trials bureaucracy: unintended consequences of well-intentioned policy. <i>Clinical Trials</i> , 2006, 3, 496-502.	0.7	78
62	Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success. <i>Science Translational Medicine</i> , 2009, 1, 10cm9.	5.8	77
63	Vein Graft Preservation Solutions, Patency, and Outcomes After Coronary Artery Bypass Graft Surgery. <i>JAMA Surgery</i> , 2014, 149, 798.	2.2	74
64	Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. <i>American Heart Journal</i> , 2014, 168, 213-219.e1.	1.2	73
65	Tying clinical research to patient care by use of an observational database. <i>Statistics in Medicine</i> , 1984, 3, 375-384.	0.8	69
66	Reengineering the National Clinical and Translational Research Enterprise: The Strategic Plan of the National Clinical and Translational Science Awards Consortium. <i>Academic Medicine</i> , 2010, 85, 463-469.	0.8	65
67	Geographic Health Information Systems: A Platform To Support The "Triple Aim". <i>Health Affairs</i> , 2013, 32, 1608-1615.	2.5	64
68	Technology-Enabled Clinical Trials. <i>Circulation</i> , 2019, 140, 1426-1436.	1.6	59
69	A Historical Perspective on Clinical Trials Innovation and Leadership. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 713.	3.8	58
70	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
71	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
72	Toward protecting the safety of participants in clinical trials. <i>Contemporary Clinical Trials</i> , 2003, 24, 256-271.	2.0	56

#	ARTICLE	IF	CITATIONS
73	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2015, 8, 473-480.	1.6	55
74	Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial. <i>Circulation</i> , 2000, 102, 1375-1381.	1.6	53
75	Digital clinical trials: creating a vision for the future. <i>Npj Digital Medicine</i> , 2019, 2, 126.	5.7	53
76	Linking Scientific Discovery and Better Health for the Nation: The First Three Years of the NIH's Clinical and Translational Science Awards. <i>Academic Medicine</i> , 2010, 85, 457-462.	0.8	52
77	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.3	52
78	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008, 5, 38-39.	0.7	51
79	Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1991, 65, 275-279.	1.8	51
80	Accelerating development of scientific evidence for medical products within the existing US regulatory framework. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 297-298.	21.5	50
81	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
82	Transforming Psychiatry into Data-Driven Medicine with Digital Measurement Tools. <i>Npj Digital Medicine</i> , 2018, 1, 37.	5.7	49
83	Return of Research Results to Study Participants. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 435.	3.8	49
84	Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis. <i>Thrombosis and Haemostasis</i> , 1992, 67, 292-296.	1.8	49
85	Rescuing clinical trials in the United States and beyond: A call for action. <i>American Heart Journal</i> , 2013, 165, 837-847.	1.2	45
86	Atrioventricular and Intraventricular Conduction Disorders in Acute Myocardial Infarction: A Reappraisal in the Thrombolytic Era. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998, 21, 2651-2663.	0.5	44
87	Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems. <i>Clinical Trials</i> , 2015, 12, 276-286.	0.7	43
88	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
89	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
90	Clinical Trials in Peripheral Vascular Disease. <i>Circulation</i> , 2014, 130, 1812-1819.	1.6	40

#	ARTICLE	IF	CITATIONS
91	Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453.	1.2	40
92	American Industry and the U.S. Cardiovascular Clinical Research Enterprise. <i>Journal of the American College of Cardiology</i> , 2011, 58, 677-680.	1.2	39
93	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	5.7	38
94	MEDICINE: Placebo-Controls in Short-Term Clinical Trials of Hypertension. <i>Science</i> , 2001, 292, 2013-2015.	6.0	38
95	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 554-561.	1.5	37
96	Principles From Clinical Trials Relevant to Clinical Practice: Part II. <i>Circulation</i> , 2002, 106, 1172-1175.	1.6	36
97	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	1.2	36
98	Embedding Cardiovascular Research Into Practice. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2037.	3.8	35
99	The Patient-Centered Outcomes Research Network. <i>North Carolina Medical Journal</i> , 2014, 75, 204-210.	0.1	35
100	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
101	Clinical Research Sites – The Underappreciated Component of the Clinical Research System. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 2025.	3.8	32
102	Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1057-1068.	1.2	32
103	Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. <i>American Heart Journal</i> , 2014, 167, 921-929.e2.	1.2	31
104	The future of humans as model organisms. <i>Science</i> , 2018, 361, 552-553.	6.0	31
105	Curbing The Cardiovascular Disease Epidemic: Aligning Industry, Government, Payers, And Academics. <i>Health Affairs</i> , 2007, 26, 62-74.	2.5	30
106	Check It, Change It. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 828-834.	0.9	30
107	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
108	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021, 42, 1464-1475.	1.0	29

#	ARTICLE	IF	CITATIONS
109	Toward a Mobile Platform for Real-world Digital Measurement of Depression: User-Centered Design, Data Quality, and Behavioral and Clinical Modeling. JMIR Mental Health, 2021, 8, e27589.	1.7	29
110	Future of Personalized Cardiovascular Medicine. Journal of the American College of Cardiology, 2018, 72, 3301-3309.	1.2	28
111	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. American Heart Journal, 2015, 170, 117-122.	1.2	27
112	Operator-Specific Outcomes. Circulation, 1996, 93, 403-406.	1.6	27
113	Defining The Balance Of Risk And Benefit In The Era Of Genomics And Proteomics. Health Affairs, 2004, 23, 77-87.	2.5	26
114	Precision Health Analytics With Predictive Analytics and Implementation Research. Journal of the American College of Cardiology, 2020, 76, 306-320.	1.2	25
115	The Future of Cardiovascular Clinical Research. JAMA - Journal of the American Medical Association, 2012, 308, 1747.	3.8	24
116	Understanding the use of observational and randomized data in cardiovascular medicine. European Heart Journal, 2020, 41, 2571-2578.	1.0	24
117	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the Project of Ex-vivo Vein graft Engineering via Transfection IV Trial. American Heart Journal, 2015, 169, 175-184.	1.2	23
118	Medication Discontinuation in the IMPROVE-IT Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005041.	0.9	23
119	Using observational data to estimate prognosis: an example using a coronary artery disease registry. Statistics in Medicine, 2001, 20, 2505-2532.	0.8	22
120	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. JACC: Heart Failure, 2013, 1, 523-530.	1.9	22
121	Stroke prevention in atrial fibrillation: re-defining "real-world data" within the broader data universe. European Heart Journal, 2018, 39, 2932-2941.	1.0	22
122	Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability. Journal of Clinical and Translational Endocrinology, 2015, 2, 26-36.	1.0	21
123	Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation. JAMA - Journal of the American Medical Association, 2019, 321, 1571.	3.8	21
124	Current Management of Mitral Valve Incompetence Associated with Coronary Artery Disease. Journal of Cardiac Surgery, 1989, 4, 25-42.	0.3	20
125	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. JACC: Heart Failure, 2015, 3, 777-785.	1.9	19
126	Pragmatic clinical trials: Emerging challenges and new roles for statisticians. Clinical Trials, 2016, 13, 471-477.	0.7	19



#	ARTICLE	IF	CITATIONS
127	Roadmap to 2030 for Drug Evaluation in Older Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 210-223.	2.3	19
128	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019, 139, 863-873.	1.6	18
129	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021, 144, 159-169.	1.6	18
130	Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 5-16.	0.9	17
131	Forging Stronger Partnerships Between Academic Health Centers and Patient-Driven Organizations. <i>Academic Medicine</i> , 2013, 88, 1220-1224.	0.8	17
132	Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 168-177.	5.1	17
133	Filling in the Evidence About Sunscreen. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2077.	3.8	17
134	Avoiding the Coming Tsunami of Common, Chronic Disease. <i>Circulation</i> , 2021, 143, 1831-1834.	1.6	17
135	Independent data monitoring committees: Preparing a path for the future. <i>American Heart Journal</i> , 2014, 168, 135-141.e1.	1.2	16
136	Cosmetics, Regulations, and the Public Health. <i>JAMA Internal Medicine</i> , 2017, 177, 1080.	2.6	16
137	Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. <i>American Heart Journal</i> , 2008, 156, 879-885.	1.2	15
138	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
139	Organizational Improvements to Enhance Modern Clinical Epidemiology. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2300.	3.8	14
140	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 840-846.	0.8	14
141	Translation of acute coronary syndrome therapies: From evidence to routine clinical practice. <i>American Heart Journal</i> , 2015, 169, 266-273.	1.2	14
142	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 389-397.	1.1	14
143	Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. <i>American Heart Journal</i> , 2001, 141, 301-305.	1.2	13
144	Portfolio of Clinical Research in Adult Cardiovascular Disease as Reflected in ClinicalTrials.gov. <i>Journal of the American Heart Association</i> , 2013, 2, e000009.	1.6	13

#	ARTICLE	IF	CITATIONS
145	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
146	A holistic approach for suppression of COVID-19 spread in workplaces and universities. <i>PLoS ONE</i> , 2021, 16, e0254798.	1.1	13
147	Evaluating the Potential Economic Attractiveness of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome. <i>Pharmacoeconomics</i> , 2000, 17, 263-272.	1.7	12
148	Benefit the patient, manage the risk: a system goal. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 269-276.	0.9	12
149	Cycle Time Metrics for Multisite Clinical Trials in the United States. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 152-160.	0.8	12
150	Predictive Models in Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 877-878.	1.6	12
151	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	1.6	12
152	Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006606.	0.9	12
153	Careers for Clinician Investigators. <i>Circulation</i> , 2009, 119, 2945-2950.	1.6	11
154	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	0.8	11
155	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	1.2	11
156	A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005, 149, S91-S99.	1.2	10
157	Towards a new order in cardiovascular medicine: re-engineering through global collaboration. <i>European Heart Journal</i> , 2010, 31, 911-917.	1.0	10
158	LCZ696: too good to be true?. <i>European Heart Journal</i> , 2015, 36, 410-412.	1.0	10
159	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0219894.	1.1	10
160	High-quality evidence to inform clinical practice. <i>Lancet, The</i> , 2019, 394, 633-634.	6.3	10
161	Return of individual research results: What do participants prefer and expect?. <i>PLoS ONE</i> , 2021, 16, e0254153.	1.1	10
162	Importance of Social Determinants in Screening for Depression. <i>Journal of General Internal Medicine</i> , 2022, 37, 2736-2743.	1.3	10

#	ARTICLE	IF	CITATIONS
163	A New Look at an Old Therapy. JAMA - Journal of the American Medical Association, 2012, 307, 1972.	3.8	9
164	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. American Journal of Medicine, 2015, 128, 297-302.	0.6	9
165	Differences in Health Outcomes between Men and Women: Biological, Behavioral, and Societal Factors. Clinical Chemistry, 2019, 65, 19-23.	1.5	9
166	Facilitating translational team science: The project leader model. Journal of Clinical and Translational Science, 2019, 3, 140-146.	0.3	8
167	Reimagining What We Measure in Atherosclerosisâ€”a â€œPhenotype Stackâ€”. Circulation Research, 2020, 126, 1146-1158.	2.0	8
168	Key issues for global cardiovascular medicine. Lancet, The, 2009, 374, 508-510.	6.3	7
169	Assessing Research Results in the Medical Literature. JAMA Internal Medicine, 2013, 173, 1053.	2.6	7
170	CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. Clinical and Translational Science, 2015, 8, 623-631.	1.5	7
171	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 2015, 5, e007901.	0.8	7
172	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. American Heart Journal, 2019, 218, 110-122.	1.2	7
173	Intravenous Heparin, Thrombolytics, and Medical Marketing. Journal of Interventional Cardiology, 1991, 4, 1-4.	0.5	6
174	Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 1996, 3, 107-115.	1.0	6
175	Establishing a Framework for Improving the Quality of Clinical and Translational Research. Journal of Clinical Oncology, 2012, 30, 1725-1726.	0.8	6
176	Big Data in the Assessment of Pediatric Medication Safety. Pediatrics, 2020, 145, .	1.0	6
177	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. Journal of Clinical Investigation, 2021, 131, .	3.9	6
178	Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. American Heart Journal, 2020, 226, 4-12.	1.2	6
179	Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Stroke. 2012, 43, .	1.0	6
180	Brachial approach to emergency cardiac catheterization during thrombolytic therapy for acute Myocardial Infarction. Catheterization and Cardiovascular Diagnosis, 1990, 20, 221-226.	0.7	5

#	ARTICLE	IF	CITATIONS
181	The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 782-786.	0.9	5
182	Large simple trials: really, it can't be that simple!. <i>European Heart Journal</i> , 2014, 35, 549-551.	1.0	5
183	Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full. <i>Clinical Trials</i> , 2018, 15, 235-239.	0.7	5
184	Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials. <i>JAMA Cardiology</i> , 2019, 4, 1129.	3.0	5
185	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	0.8	5
186	Mapping and quantification of the twitter footprint of cardiologists. <i>European Heart Journal Digital Health</i> , 2021, 2, 374-378.	0.7	5
187	Cigarette Smoking. <i>Circulation</i> , 2000, 102, 1340-1341.	1.6	4
188	A Virtuous Cycle to Improve Hypertension Outcomes at a National Level. <i>Hypertension</i> , 2009, 53, 105-107.	1.3	4
189	Better Late Than Never. <i>JACC: Heart Failure</i> , 2013, 1, 112-114.	1.9	4
190	Patient-Centered Outcomes Composites. <i>Circulation</i> , 2014, 130, 1223-1224.	1.6	4
191	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes—Authors' reply. <i>Lancet</i> , 2014, 384, 1097-1098.	6.3	4
192	Resourcing Drug Development Commensurate With its Public Health Importance. <i>JACC Basic To Translational Science</i> , 2016, 1, 309-312.	1.9	4
193	Life expectancy and voting patterns in the 2020 U.S. presidential election. <i>SSM - Population Health</i> , 2021, 15, 100840.	1.3	4
194	The Ecosystem to Support People with Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	4
195	Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1997, 4, 100-111.	3.1	3
196	Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective. <i>Journal of Thrombosis and Thrombolysis</i> , 1997, 4, 415-423.	1.0	3
197	Rational use of medications: If Canada can't do it .... <i>Cmaj</i> , 2009, 181, 15-16.	0.9	3
198	Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension. <i>JAMA Internal Medicine</i> , 2018, 178, 63.	2.6	3

#	ARTICLE	IF	CITATIONS
199	Individual risk prediction using data beyond the medical clinic. <i>Cmaj</i> , 2018, 190, E947-E948.	0.9	3
200	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2014661.	2.8	3
201	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. <i>Diabetes Care</i> , 2020, 43, 2485-2492.	4.3	3
202	Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. <i>BMJ Open</i> , 2022, 12, e054741.	0.8	3
203	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 242-266.	1.0	2
204	Commentary on Vickers. <i>Clinical Trials</i> , 2014, 11, 626-627.	0.7	2
205	The new era of clinical research: Using data for multiple purposes. <i>American Heart Journal</i> , 2014, 168, 133-134.	1.2	2
206	Warning About Shortcuts in Drug Development. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
207	Providing Individual Research Results to Participants—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2601.	3.8	2
208	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018, 122, 1451-1458.	0.7	2
209	Oral Fluoroquinolones. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1451-1453.	1.2	2
210	Employ Cybersecurity Techniques Against the Threat of Medical Misinformation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 207.	3.8	2
211	Standardized classification and framework for reporting and interpreting medication non-adherence in clinical trials. <i>European Heart Journal</i> , 2019, 40, 2086-2088.	1.0	2
212	Translating clinical trials into practice. <i>Texas Heart Institute Journal</i> , 2006, 33, 192-6.	0.1	2
213	The GUSTO Trials. <i>Journal of Interventional Cardiology</i> , 1999, 12, 13-31.	0.5	1
214	Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?. <i>Statistics in Medicine</i> , 2002, 21, 2889-2897.	0.8	1
215	Matching resources to treatment decisions for patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2002, 25, 2-8.	0.7	1
216	A time of accelerated change in academic cardiovascular medicine. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1957-1965.	1.2	1

#	ARTICLE	IF	CITATIONS
217	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. Drug Information Journal, 2007, 41, 491-499.	0.5	1
218	In search of the efficient way to medical decisions: The case of acute heart failure syndrome. American Heart Journal, 2012, 164, 135-137.	1.2	1
219	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 2016, 1, 93-100.	2.7	1
220	Evaluating Evolving Technologies in a Time of Rapid Change. JAMA Cardiology, 2017, 2, 830.	3.0	1
221	Finding ideal blood pressure targets in ischaemic stroke: prospective insight or retrospective guesswork?. European Heart Journal, 2017, 38, 2836-2837.	1.0	1
222	A Beginning to Principles of Ethical and Regulatory Oversight of Patient-Centered Research. Annals of Internal Medicine, 2018, 169, 579.	2.0	1
223	Reframing Global Variation in Heart Failure Trials. JACC: Heart Failure, 2019, 7, 347-349.	1.9	1
224	Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. Circulation, 2019, 140, 1860-1864.	1.6	1
225	Task Force 2: Investigator Participation in Clinical Research. Circulation, 2004, 110, 2517-2524.	1.6	1
226	Thrombolytic therapy for myocardial infarction: A perspective of clinical trialists. Clinical Cardiology, 1992, 15, 143-144.	0.7	0
227	New Agents, New Trials, New Solutions. Journal of Thrombosis and Thrombolysis, 1998, 5, S151-S159.	1.0	0
228	Introduction: Redefining acute coronary syndrome care in the era of aggressive revascularization. Clinical Cardiology, 2002, 25, 1-1.	0.7	0
229	Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry. , 2005, , 287-314.		0
230	Response to The J-Point Revisited. Hypertension, 2008, 51, .	1.3	0
231	Commentary on Anand <i>et al</i> .. Clinical Trials, 2011, 8, 724-725.	0.7	0
232	Rationale for key elements of Sino-American collaboration in clinical research. Journal of Translational Medicine, 2012, 10, .	1.8	0
233	Work and Cardiovascular Disease in China. JAMA Network Open, 2018, 1, e184815.	2.8	0
234	Large Clinical Trials and Registries—Clinical Research Institutes. , 2018, , 411-444.		0

#	ARTICLE	IF	CITATIONS
235	Proposals to Lower Medication Costs—Reply. JAMA - Journal of the American Medical Association, 2019, 322, 982.	3.8	0
236	Consent for Research Participation in Practice. American Journal of Bioethics, 2019, 19, 19-21.	0.5	0
237	Improving Clinical Outcomes in the Era of Information Ubiquity. Journal of the American Society of Nephrology: JASN, 2019, 30, 7-12.	3.0	0
238	Monitoring the Pediatric Clinical Trials Enterprise. Pediatrics, 2021, 148, e2021051589.	1.0	0
239	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	1.6	0
240	Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension.. Blood, 2004, 104, 1583-1583.	0.6	0
241	Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial. Circulation, 2014, 130, .	1.6	0
242	A View from Academia. , 0, , 67-76.		0
243	Early ischemia after thrombolytic therapy for a first myocardial infarction was associated with increased total cardiac events and emergency revascularization. ACP Journal Club, 1993, 119, 82.	0.1	0
244	Atenolol reduced ischemia-related events in asymptomatic ischemia. ACP Journal Club, 1995, 122, 32.	0.1	0